Dairy Products, Diabetes and Genetics

CHU de Quebec-Universite Laval33 enrolled

Overview

This study will investigate the in-depth the benefits of dairy consumption on glucose metabolism in patients at risk of type 2 diabetes using novel genomics methodology.To do so, 33 individuals at risk of type 2 diabetes will be randomly subjected to an intervention study including a 6-week intensive dairy product consumption period and a 6-week dietary counselling period.

More than 9 million Canadians are living with diabetes or prediabetes. Type 2 diabetes is a disorder characterized by high blood glucose. Dietary modification is a key component in type 2 diabetes management. For example, dairy product consumption has beneficial effects on metabolic health. Yet, researchers have shown that mixed results exists for insulin sensitivity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Insulin Sensitivity Type2 Diabetes

Interventions

Increased dairy productBEHAVIORAL

Dietary counsellingBEHAVIORAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Caucasian men and postmenopausal women (absence of menstrual cycles for \>12 months) aged \>18 yrs; * BMI between 25-40 kg/m2; * Hyperinsulinemia (fasting plasma insulin \>90 pmol/l); * Fasting plasma glucose (FPG) \<7.0 mmol/l; HbA1c \<6.5%); * If treated with lipid-lowering agents, the dose must have been stable over the last 3 months; * Stable body weight (±5%) for 3 months; * Willing to consume study foods and able to follow protocol and give informed consent. Exclusion Criteria: * Failure to meet any one or more of the inclusion criteria; * Diagnosis of type 2 diabetes; * High dairy consumption ( 2 servings/day or more); * Major surgery in the 3 months prior to study onset; * Smoking; * Incompatibility with dairy consumption (allergy, intolerance or dislike); * Inflammatory bowel disease or other gastrointestinal disorder influencing gastrointestinal motility or nutrient absorption; * Medications known to affect lipid and glucose metabolism other than those used to treat hypertension or dyslipidemia; * Diseases known to affect glucose metabolism.

Locations (1)

Research Center CHU de Quebec-Université Laval

Québec, Quebec, Canada

Outcomes

Primary Outcomes

Change from baseline to 6 weeks in insulin sensitivity between high dairy and dietary counselling phases

2h-oral glucose tolerance test (OGTT)